Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs Geron Corporation

A Tale of Two Pharmaceutical Giants: Cost Efficiency Over Time

In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Teva Pharmaceutical Industries Limited and Geron Corporation from 2014 to 2023. Teva, a global leader, consistently reported a cost of revenue exceeding $8 billion annually, peaking at approximately $11.56 billion in 2017. In contrast, Geron, a smaller biotech firm, showed more variability, with costs ranging from $783,000 in 2021 to $123.74 million in 2023. Notably, Geron's cost of revenue surged by over 15,700% from 2021 to 2023, reflecting strategic shifts or increased operational activities. Meanwhile, Teva's costs decreased by about 31% from 2017 to 2023, indicating improved efficiency or strategic cost-cutting measures. This comparison highlights the diverse financial strategies and challenges faced by pharmaceutical companies in maintaining cost efficiency.